Deamidated Gluten Protein Specific Neutra™ Antibody Products

Are you struggling with unreliable biomarkers for celiac disease diagnosis or facing challenges in detecting gluten-induced immune responses? Creative Biolabs' deamidated gluten protein specific Neutra™ antibody products leverage advanced epitope-specific engineering to deliver ultra-sensitive, high-affinity antibodies. These tools enable accurate identification of deamidated gluten epitopes, streamlining diagnostic workflows and enhancing research into gluten-related pathologies.

Introduction to Deamidated Gluten Protein

Deamidated gluten protein arises from the post-translational modification of gliadin peptides, primarily through enzymatic deamidation mediated by tissue transglutaminase (tTG). This process converts glutamine residues to glutamic acid, enhancing immunogenicity and enabling recognition by HLA-DQ2/8 molecules in genetically predisposed individuals. Deamidated gluten is a hallmark antigen in celiac disease, driving adaptive immune responses and epitope spreading.

• Structure

Structurally, deamidated gluten peptides adopt a conformationally stable, negatively charged surface due to the introduction of acidic residues. This altered charge facilitates stronger binding to HLA-DQ2/8 receptors, a critical step in triggering T-cell activation. The immunodominant epitopes, such as α-gliadin 33-mer and γ-gliadin 26-mer, become accessible post-deamidation, forming stable complexes with tTG that perpetuate autoimmune reactions.

• Related Signaling Pathways

Deamidated gluten activates the NF-κB and MAPK pathways in intestinal epithelial cells, promoting pro-inflammatory cytokine release (e.g., IL-15, IFN-γ). Concurrently, it amplifies antigen presentation via dendritic cells, driving T-helper 1 (Th1) polarization and cytotoxic T-cell infiltration. These pathways synergize to damage intestinal villi, perpetuating malabsorption and systemic inflammation.

• Related Diseases

Celiac disease, an autoimmune enteropathy triggered by deamidated gluten, affects 1% of the global population. Symptoms include chronic diarrhea, weight loss, and extra-intestinal manifestations like dermatitis herpetiformis. Untreated, it leads to osteoporosis, anemia, and lymphoma. Early detection of deamidated gluten-specific antibodies is critical for diagnosis and monitoring.

Fig.1 Deamidation of gluten in celiac disease pathogenesis.¹

Applications of Anti-Deamidated Gluten Protein Neutralizing Antibodies

• Enhancing Celiac Disease Diagnostic Accuracy

Deamidated gluten-specific antibodies are pivotal in differentiating celiac disease from non-celiac gluten sensitivity. Their high specificity reduces false-positive rates in serological testing, particularly in pediatric and IgA-deficient populations.

• Monitoring Disease Progression and Treatment Efficacy

Quantifying antibody titers post-gluten-free diet initiation provides objective metrics for mucosal healing and compliance, guiding personalized patient management.

• Supporting Therapeutic Development

Neutralizing antibodies enable preclinical evaluation of therapies targeting deamidated gluten-tTG complexes, such as enzyme inhibitors or immune tolerance inducers.

• Investigating Gluten-Related Autoimmunity Mechanisms

In vitro and in vivo models utilizing these antibodies elucidate the role of epitope spreading in refractory celiac disease or tTG-independent pathways.

Our Anti-Deamidated Gluten Protein Antibodies

Creative Biolabs' antibodies are engineered to exclusively recognize deamidated gliadin epitopes, eliminating cross-reactivity with native gluten proteins. Their applications span:

• Diagnostic specificity: Detecting anti-deamidated gliadin antibodies (DGP-IgA/IgG) with >95% sensitivity in celiac disease screening.
• Research utility: Mapping conformational epitopes to study immune evasion or therapeutic targeting.

These antibodies undergo rigorous validation in ELISA, immunohistochemistry, and multiplex assays, ensuring reproducibility in clinical and research settings.

Creative Biolabs' deamidated gluten protein specific Neutra™ antibody products empower researchers and clinicians to overcome challenges in celiac disease diagnostics and therapy development. With unmatched specificity and validation across platforms, our antibodies are your gateway to advancing gluten-related research. Contact our scientific team today to discuss customized solutions for your project.

REFERENCE

1. Balakireva, Anastasia V., and Andrey A. Zamyatnin Jr. "Properties of gluten intolerance: gluten structure, evolution, pathogenicity and detoxification capabilities." Nutrients 8.10 (2016): 644. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/nu8100644